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To the Editor 
Dyskeratosis congenita (DC) and its severe form Hoyeraal-Hreidarsson syndrome (HHS) are 
rare and have life threatening failure of hematopoiesis. Typically, DC patients present with 
disease features such as nail dystrophy, oral leukoplakia and abnormal skin pigmentation along 
with peripheral pancytopenia and marrow hypoplasia with strong predisposition to cancer.1 In 
DC, hematopoietic failure occurs due to critical shortening of telomeres2,3 enhancing DNA 
damage response4,5 leading to premature senescence of hematopoietic stem cells.6 
 
Telomeres are lengthened by the enzyme telomerase, which constitutes RNA template (TERC) 
and the catalytic reverse transcriptase (TERT). Variants affecting telomerase complex (TERT 
and TERC), telomerase stability (DKC1, NOP10, NHP2, PARN and NAF1), telomerase 
trafficking (WRAP53), and telomere replication (CTC1 and RTEL1) have been identified in 
majority of DC and HHS cases. The shelterin complex proteins (TRF1, TRF2, RAP1, TIN2, 
POT1 and TPP1) that serve to protect telomeres are critical for telomerase function.7 The first 
DC variants to be described in a shelterin component were found in TINF2.8 Variants in ACD 
encoding TPP1 were later described in two independent families,9,10 The first was in a family 
with a history of aplastic anemia, in which the index case had pancytopenia at 8 years of age 
and was heterozygous for the ACD variant c.499-501del; p.K170 del (K170Δ) that segregated 
as an autosomal dominant trait.9 The proband’s mother presented with thrombocytopenia in her 
twenty’s and was later diagnosed with myelodysplasia. Her grandmother had mild macrocytic 
anaemia associated with hypocellular bone marrow. The second case, reported by Kocak et al 
in 2014,10 had several features of HHS, had the same K170Δ variant on one allele along with 
c.1471 C>T; p.P491T on the other, suggesting an autosomal recessive inheritance.10 It is of 
interest that in this family, the proband’s father, who carried the K170Δ variant, had short 
telomeres but lacked any disease features. Structural and functional studies of K170Δ  have not 
demonstrated a dominant negative effect on TPP1 function, but instead it is suggested that 
dosage of TEL patch (patch of amino acids involved in telomerase binding on the surface of 
TPP1) is responsible for telomere shortening.11,12  
The evidence in support of causality in the BMF patients is largely derived from functional 
analysis of the variants themselves, rather than being statistically derived or based on the 
strength of a significant allelic series.9-11 It remains to be established as to how loss of function 
(LOF) variants in ACD (frameshift, splice donor/acceptor or stop gain) can have a significant 
heterozygous frequency in the Genome aggregation database (gnomAD), where 57 of these 
variants are described (representing ~6 in 10,000 individuals). Given this frequency of 
heterozygous LOF ACD variants in the control population, together with the variable pattern of 
inheritance and very different clinical presentations in the only two families described to date, 
the case for ACD as a proven disease-causing locus remains uncertain.  
By whole exome sequencing in a series of genetically uncharacterised patients (n=228) 
presenting with DC or constitutional bone marrow failure (BMF) from our DC Registry, we 
identified nonsynonymous ACD variants in 5 unrelated cases (supplemental Table 1). In two of 
these (index cases of families 1 and 2, Figure 1A) the ACD variants were homozygous 
(supplemental Table 1). The index case of family 1 harbors the homozygous variant c.280C>T; 
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p.V94I, which has been reported once in the homozygous state and 191/270022 alleles in 
heterozygous state on gnomAD. This index case, aged 38 years had thrombocytopenia, short 
stature, pulmonary abnormalities and limbal stem cell deficiency (LSCD; supplemental Table 2 
and supplemental Figure 1A-B). His older sister, who was heterozygous for this variant had 
short stature, pulmonary abnormalities and LSCD but no hematopoietic defect (supplemental 
Table 2). The index case from family 2 had a novel homozygous missense variant, c.284T>A, 
p.L95Q that has not been reported on gnomAD. The index case, aged 12 years presented with 
leukoplakia and subsequently developed BMF and immunodeficiency (supplemental Figure 1C-
E and supplemental Table 2). His older brother had died of aplastic anemia (supplemental Table 
2). No other obvious candidate genes that are previously known to cause BMF are identified in 
these two cases (supplemental Table 3).  Both homozygous variants identified in families 1 and 
2 are predicted to be damaging by CADD score (supplemental Table 1) and affect the highly 
conserved oligonucleotide binding (OB)-fold domain in TPP1 that is implicated in telomerase 
binding, recruitment and function at telomeres (Figure 1B and supplemental Figure 3C).10,12  
 
Telomere length measurement by MMqPCR13 revealed short telomeres in the index case of 
family 1, just below the tenth centile when compared to his heterozygous sister and controls 
(n=218; Figure 1C and supplemental Table 2). Index case from family 2 had very short 
telomeres, below the first centile as measured by MMqPCR (Figure 1C) and Flow-FISH method 
(supplemental Figure 2). His heterozygous parents also had short telomeres (Figure 1C, 
supplemental Figure 2 and supplemental Table 2) but were asymptomatic. Telomere labelling 
using a Tel-Cy3 probe (PNA bioscience) on metaphase spreads of EBV-transformed B-
lymphoblasts (LCLs) derived from the index case of family 2 (L95Q) revealed reduced telomere 
signal when compared to age matched control (Figure 1D). Telomere chromatin 
immunoprecipitation (ChIP) assay in TPP1 shRNA treated HEK293 cells expressing TPP1-
L95Q variant (supplemental; Figure 3A and B), revealed no significant change in its association 
with telomeres (Figure 1E). Furthermore, mimicking TPP1-L95Q variant in S. pombe (Tpz1-
L5Q) also induced telomere shortening (Figure 1F and supplemental Figure 3C and D).15 These 
data suggest that the TPP1-L95Q OB-fold variant interferes with telomere maintenance despite 
localising to telomeres.  
 
The TEL patch in the OB-fold domain is essential for telomerase recruitment at telomeres 
(Figure 2A).12,16 TPP1 OB-fold crystal structure reveals both V94 and L95 residues that are 
mutated in our cases are present in the N terminus of OB-fold (NOB) domain, forming a 
hydrophobic cleft that extends the TEL patch (Figure 2A).12, 14 Mutating both these residues 
simultaneously reduces telomerase processivity, abrogates telomerase recruitment to 
telomeres, and shortens telomeres of human cells in culture.14 In line with this, co-
immunoprecipitation and quantitative TRAP analysis in HeLa nuclear lysates, demonstrated that 
both TPP1-V94I and TPP1-L95Q have impaired ability to bind TERT (Figure 2B and C) and 
reduced TPP1 associated telomerase activity in comparison to wild-type, when overexpressed 
(Figure 2D and E).  These results indicate that both OB-fold residues V94 and L95 participate in 
TPP1–telomerase interaction and regulate telomerase activity. Telomerase association with 
TPP1 OB-fold, is important for its maturation, traffic and recruitment to telomeres via Cajal 
bodies.17 In HeLa cells, when over expressed TPP1-L95Q showed diffused punctate in the 
nucleoplasm, which do not colocalise with coilin that resides in Cajal bodies (Figure 2F and G). 
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This is similar for TPPI-K170Δ and the other artificial TEL patch variants described previously.9-
12,14 Interestingly abnormal cytoplasmic staining of TPP1-L95Q (Figure 2H and I) and reduction 
in telomerase activity is observed in the patient cells (Figure 2J), indicating defects in 
telomerase maturation pathway.  
In summary, we report the first instance of homozygous TPP1 OB-fold variants in patients from 
two unrelated families who have overlapping phenotypes with DC.18 As these variants cluster in 
the TEL patch of TPP1, which is essential for telomerase recruitment to telomeres, they provide 
in-vivo evidence in humans for the biological importance of this TPP1 OB-fold domain.  
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Figure 1. (A) Family trees showing the segregation of ACD variants. -/-, homozygous variant; 
+/-, heterozygous; +/+, wild type. Arrows indicate index cases that underwent whole exome 
sequencing. Grey colour indicates presence of some somatic features [short stature and limbal 
stem cell deficiency (LSCD)] but no hematopoietic abnormality. N/A; DNA not available (B). 
TPP1 topology showing three functional domains; telomerase interacting OB-fold, POT1 
recruitment domain (RD) and TIN2 interacting domain (TID) separated by serine threonine (S/T) 
motif. (C) Whole blood telomere lengths of index cases and family members are indicated 
(family 1 in green and family 2 in red). Telomere lengths are reduced in index cases (squares) 
when compared with heterozygous (diamond) and wild type (triangle) family members and 
controls (n = 218). (D) Telomere FISH of EBV-transformed lymphoblasts derived from index 
case in family 2 and a healthy control. (E) Telomere ChIP of myc- POT1, FLAG- TPP1 wild type 
(WT) and OB-fold variants, expressed in HEK293 cells. Dot blot shows input chromatin used in 
each immunoprecipitation (top). Immunoprecipitation with an anti-POT1 antibody, anti-FLAG 
antibody, anti-rabbit (Rb) IgG control and protein G beads alone. Expression of TPP1 WT and 
For personal use only.on August 6, 2018. by guest  www.bloodjournal.orgFrom 
 6
variants is demonstrated by immunoblotting in the bottom panel. TPP1 p.K170Δ variant was 
used as positive control as it has been previously shown to bind to telomeres.9,10 (F) Telomere 
lengths of S. pombe strains harboring Tpz1 (orthologue of human ACD/TPP1) OB-fold variants. 
Tpz1 K75A yeast strains with previously confirmed short telomeres is used as a positive 
control.15 Arrow indicates extremely faint telomeric band due to presence of very telomeric DNA 
present in L5Q strain. LC refers to loading control of genomic DNA stained by ethidium bromide. 
WT refers to wildtype. 
 
Figure 2. (A) In silico model of the TPP1 OB-fold crystal structure (PDB id: 2I46)16 using UCSF 
CHIMERA, an extensible molecular modelling software. Previously described TPP1-TEL patch 
residues are denoted in black 12 and the patient variants in BMF patients identified to date are 
denoted in red. OB-fold ribbon structure is depicted in blue and surface hydrophobicity preset is 
shown with amino acid hydrophobicity in the Kyte-Doolittle scale with colors ranging from 
dodger blue for the most hydrophilic to white at 0.0 to orange for the most hydrophobic. ‘NOB’ 
refers to N terminus of OB-fold domain that is recently described in telomerase binding.14 (B and 
C) Immunoblotting of FLAG pull down (PD) complexes from nuclear extracts of HEK293 cells 
that are treated with TPP1 3’UTR shRNA and expressing shRNA resistant FLAG-TPP1 variants 
along with TERT and POT1. ‘IN’ refers to 15% Input. Note the reduction in TERT signal pulled 
by the TPP1 OB-fold variants compared to input and WT. (D and E) HeLa cells expressing Flag-
tagged wild-type TPP1 were analyzed for TPP1-associated endogenous telomerase activity by 
immunoprecipitation and subsequent TRAP analysis. Results from TRAP assay were 
normalized based on the amount of eluted TPP1 protein. (F and G) Double 
immunofluorescence was used to detect the FLAG-TPP1 proteins (green) and coilin (a Cajal 
body marker, red) in HeLa cells. Yellow (merged green + red) spots indicated by arrows show 
co-localization of TPP1 with coilin are quantified by counting cells from different fields of view 
(n=2). (H and I) Endogenous TPP1 co-localisation with coilin in control and patient (TPP1 
p.L95Q) B lymphoblastoid cells; WT refers to wildtype. (J) Relative levels of telomerase activity 
in the patient and age matched control B lymphoblastoid cells at passage 5 were determined by 
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